Substandard medicines in resource-poor settings: A problem that can no longer be ignored

Tropical Medicine and International Health

Volumn 13, Issue 8, 2008, Pages 1062-1072

  Caudron, J M ^a,b   Ford, N ^a   Henkens, M ^a   Mace C ^a   Kiddle Monroe, R ^a   Pinel, J ^a,b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b AEDES Foundation   (Belgium)

Author keywords

Contamination; Drug export; Quality assurance; Quality standards; Substandard medicines

Indexed keywords

ACETYLSALICYLIC ACID; AMODIAQUINE; AMOXICILLIN; AMPICILLIN; AMPICILLIN PLUS CLOXACILLIN; ARTEMISININ DERIVATIVE; CHLORAMPHENICOL; CHLOROQUINE; CLAVULANIC ACID; COTRIMOXAZOLE; DIAZEPAM; ERGOMETRINE; ERYTHROMYCIN; FUROSEMIDE; METRONIDAZOLE; NELFINAVIR; PARACETAMOL; PYRIMETHAMINE; RANITIDINE; RIFAMPICIN; SALBUTAMOL; SULFADOXINE; TETRACYCLINE; TUBERCULOSTATIC AGENT; VITAMIN B GROUP;

DEVELOPING WORLD; DRUG; MEDICINE; PHARMACEUTICAL INDUSTRY; PUBLIC HEALTH;

CONCENTRATION (PARAMETERS); DEVELOPING COUNTRY; DRUG CONTAMINATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG PACKAGING; DRUG QUALITY; DRUG SCREENING; DRUG STABILITY; DRUG SURVEILLANCE PROGRAM; DRUG USE; GOVERNMENT REGULATION; HEALTH CARE POLICY; REVIEW; SOCIAL STATUS; WORLD HEALTH ORGANIZATION;

DEVELOPING COUNTRIES; DRUG CONTAMINATION; DRUG INDUSTRY; DRUG LABELING; FRAUD; HUMANS; PHARMACEUTICAL PREPARATIONS; POVERTY; QUALITY CONTROL; WORLD HEALTH ORGANIZATION;

EID: 48349102509     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2008.02106.x     Document Type: Review

References (67)

1. Aldhous P (2005) Murder by medicine. Nature 434, 132 136.
2. Amin AA, Snow RW Kokwaro GO (2005) The quality of sulphadoxine- pyrimethamine and amodiaquine products in the Kenyan retail sector. Journal of Clinical Pharmacological Therapy 30, 559 565.
3. Andriollo O, Machuron L, Videau JY, Abelli C, Plot S Muller D (1997) Supplies for humanitarian aid and development countries: the quality of essential multisources drugs. STP Pharma Pratiques 8, 137 155.
4. Arya SC (1995) Inadvertent supply of substandard drugs. World Health Forum 16, 269.
5. Atemnkeng MA, De Cock K Plaizier-Vercammen J (2007) Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Tropical Medicine and International Health 12, 68 74.
6. Ba A, Bauer M, Hamdani H, de la Torre N, Videau JY Yameogo O (2005) Comparative behavioural study in dissolution of various Glibenclamide generic tablets with princeps drugs. STP Pharma Pratiques 15, 213 230.
7. Bauer M, Couteau A, Montjanel F, Pages M, Videau JY Yameogo O (2002) Effects of the physical characteristics of frusemide on its release from generic tablets. STP Pharma Pratiques 12, 76 84.
8. Behrens RH, Awad AI Taylor RB (2002) Substandard and counterfeit drugs in developing countries. Tropical Doctor 32, 1 2.
9. Carpenter J (2004) A Review of Drug Quality in Asia with Focus on Anti-Infectives. United States Pharmacopeia, Rockville, MD.
10. Cavenaghi R (1989) Rifampicin raw material characteristics and their effect on bioavailability. Bulletin of the International Union against Tubercle Lung Disease 64, 36 37.
11. Donnelly J (2005) AIDS Drugs Hit Roadblock in Africa - Dispute Over Generics Stalls Treatment Efforts. Boston Globe, Boston.
12. European Commission (2003) Directive 2003/94/EC: Principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use. Official Journal L 262, 22 26.
13. European Commission Humanitarian Aid Department (2006) Review of Quality Assurance (QA) Mechanisms for Medicines and Medical Supplies in Humanitarian Aid. European Commission Humanitarian Aid - Concept Paper, Brussels.
14. Fawaz F Millet P (2006) L'artésunate: quelles précautions faut-il prendre pour la conservation des comprimés? ReMeD 33, 16. http://www.remed.org/Composition1_J33_2.pdf.
15. FDA (2006) Guidance for Industry Testing of Glycerin for Diethylene Glycol. US Food and Drug Administration, Rockville, MD.
16. Figueras A, Pedrós C, Valsecia M Laporte JR (2002) Therapeutic ineffectiveness: heads or tails? Drug Safety 25, 485 487.
17. Jayasena K (1985) Drugs-registration and marketing practices in the Third World. Development Dialogue 2, 38 47.
18. Kelesidis T, Kelesidis I, Rafailidis PI Falagas ME (2007) Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. Journal of Antimicrobial Chemotherapy 60, 1 23.
19. Kibwage IO, Otego JO, Maitai CK, Rutere G, Thuranira J Ochieng A (1992) Drug quality control work in Daru: observations during 1983-6. East African Medical Journal 69, 577 580.
20. Laserson KF, Kenyon AS, Kenyon TA, Layloff T Binkin NJ (2001) Substandard tuberculosis drugs on the global market and their simple detection. International Journal of Tubercle and Lung Disease 5, 448 454.
21. Lon CT, Tsuyuoka R, Phanouvong S et al. (2006) Counterfeit and substandard antimalarial drugs in Cambodia. Transactions of the Royal Society of Tropical Medicine and Hygiene 100, 1019 1024.
22. Maponga C Ondari C (2003) The Quality of Antimalarials. A Study in Selected African Countries. WHO, Geneva.
23. Minzi OM, Moshi MJ, Hipolite D et al. (2003) Evaluation of the quality of amodiaquine and sulphadoxine/pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam Tanzania. Journal of Clinical and Pharmacological Therapy 28, 117 122.
24. Moride Y, Haramburu F, Requejo AA et al. (1997) Under-reporting of adverse drug reactions in general practice. British Journal of Clinical Pharmacology 43, 177 181.
25. Nazerali H Hogerzeil H (2003) The quality and stability of essential drugs in rural Zimbabwe: controlled longtitudinal study. British Medical Journal 317, 512 513.
26. Newton PN, Green MD, Fernández FM, Day NP White NJ (2006) Counterfeit anti-infective drugs. Lancet Infectious Diseases 6, 602 613.
27. Newton PN, Fernández FM, Plançon A et al. (2008) A Collaborative Epidemiological Investigation into the Criminal Fake Artesunate Trade in South East Asia. PLoS Medicine 5, 209 219.
28. O'Brien KL, Selanikio JD, Hecdivert C et al. (1998) Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. Journal of the American Medical Association 279, 1175 180.
29. Omer AIH (1990) Stability of drugs in the tropics. A study in Sudan. Tropical Doctor 3, 129 p.
30. Onoja AL, Adu FD Tomori O (1992) Evaluation of measles vaccination programme conducted in two separate health centres. Vaccine 10, 49 52.
31. Pinheiro E, Vasan A, Kim JY, Lee E, Guimier JM Perriens J (2006) Examining the production costs of antiretroviral drugs. AIDS 20, 1745 1752.
32. Po ALW (2001) Too much, too little, or none at all: dealing with substandard and fake drugs. Lancet 357, 1904.
33. Rassool GH (2004) Substandard and counterfeit medicines. Journal of Advanced Nursing 46, 338 339.
34. ReMeD (1995) La Qualité des médicaments sur le marché pharmaceutique africain: étude analytique dans trois pays: Cameroun, Madgascar, Tchad. Action Programme on Essential Drugs. WHO, Geneva.
35. Risha P, Msuya Z, Ndomondo-Sigonda M Layloff T (2006) Proficiency testing as a tool to assess the performance of visual TLC quantitation estimates. Journal of AOAC International 89, 1300 1304.
36. Roy J (1994) The menace of substandard drugs. World Health Forum 15, 406 407.
37. Shakoor O, Taylor RB Behrens RH (1997) Assessment of the incidence of substandard drugs in developing countries. Tropical Medicine and International Health 2, 839 845.
38. Singh S Mohan B (2003) A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products. International Journal of Tubercle and Lung Disease 7, 298 303.
39. Singh J, Dutta AK, Khare S et al. (2001) Diethylene glycol poisoning in Gurgaon, India, 1998. Bulletin of the World Health Organization 79, 88 95.
40. Smine A (2002) Malaria Sentinel Surveillance Site Assessment. Mekong Region. United States Pharmacopoeia, Rockville, MD.
41. Stenson B, Lindgren BH, Syhakhang L Tomson G (1998) The quality of drugs in private pharmacies in the Lao People's Democratic Republic. International Journal of Risk and Safety in Medicine 11, 243 249.
42. Syhakhang L, Lundborg CS, Lindgren B Tomson G (2004) The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999. Pharmacy World & Science 26, 333 338.
43. Taylor RB, Shakoor O, Behrens RH et al. (2001) Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 357, 1933 1936.
44. US Pharmacopeia (2008) Available at http://www.uspdqi.org/pubs/other/GHC- DrugQualityMatrix.pdf.
45. Verduin-Muttiganzi R Verduin-Muttiganzi G (1998) Assessment of the incidence of substandard drugs in developing countries. Tropical Medicine and International Health 3, 602.
46. Videau JY (2006) Quality of medicines in least developed countries. Medecine Tropicale 66, 533 537.
47. Wertheimer AI, Chaney NM Santella T (2003) Counterfeit pharmaceuticals: current status and future projections. Journal of the American Pharmacists' Association 43, 710 717.
48. WHO (1988) World Health Assembly Resolution WHA41.16: Rational Use of Drugs. WHO, Geneva.
49. WHO (1997) Quality Assurance of Pharmaceuticals, A Compendium of Guidelines and Related Materials, Vol. 1. WHO, Geneva
50. WHO (1999a) World Health Assembly Resolution WHA52.19. Revised Drug Strategy. WHO, Geneva.
51. WHO (1999b) Fixed Dose Combination Tablets for the Treatment of Tuberculosis. WHO, Geneva.
52. WHO (1999c) Guidelines for the Development of Measures to Combat Counterfeit Medicines. WHO, Geneva.
53. WHO (1999d) Quality Assurance of Pharmaceuticals, A Compendium of Guidelines and Related Materials, Vol. 2. WHO, Geneva.
54. WHO (2003). Good Manufacturing practices for pharmaceutical products: main principles. In : WHO Expert Committee on Specifications for Pharmaceutical Preparations. WHO Technical Report Series. 908.
55. WHO (2004a) WHO Medicines Strategy 2004-2007. http://whqlibdoc.who.int/ hq/2004/WHO_EDM_2004.5.pdf.
56. WHO (2004b) Report of the pre XI ICDRA Satellite workshop on counterfeit drugs. Madrid: 13-14 February. http://www.who.int/medicines/services/ counterfeit/Pre_ICDRA_Conf_Madrid_Feb2004.pdf.
57. WHO (2004c) Quality Assurance of Pharmaceuticals. A Compendium of Guidelines and Related Materials, Vol. 2. WHO, Geneva.
58. WHO (2006a) WHO Consultation on Regulatory Technical Package and Model for Regulatory Decision Making. WHO, Geneva.
59. WHO (2006b) The Interagency Emergency Health Kit. http://www.who.int/ medicines/publications/WHO_PSM_PAR_2006.4.pdf.
60. WHO (2006c) Technical Report Series 937. http://whqlibdoc.who.int/trs/ WHO_TRS_937_eng.pdf.
61. WHO (2006d) International Medical Products Anti-Counterfeiting Taskforce. http://www.who.int/medicines/services/counterfeit/faqs/count_q-a/en/index.html.
62. WHO (2006e) A model quality assurance system for procurement agencies (Recommendations for quality assurance systems focusing on prequalification of products and manufacturers, purchasing, storage and distribution of pharmaceutical products). WHO Technical Report Series 937.
63. WHO (2006f) The International Pharmacopeia. http://www.who.int/medicines/ publications/pharmacopoeia/en/index.html.
64. WHO (2006g) Declaration of Rome: Conclusions and Recommendations of the WHO International Conference on Combating Counterfeit Medicines. 18 February. http://www.who.int/medicines/services/counterfeit/RomeDeclaration.pdf.
65. WHO (2007a). Model List of Essential Medicines. http://www.who.int/ medicines/publications/EssMedList15.pdf.
66. WHO (2007b) Specifications for Pharmaceutical Preparations. http://www.who.int/entity/medicines/publications/pharmprep/en/index.html.
67. Wondemagegnehu E (1999) Counterfeit and Substandard Drugs in Myanmar and Viet Nam. WHO, Geneva.